AU2021213840A1 - Bispecific T cell engagers - Google Patents

Bispecific T cell engagers Download PDF

Info

Publication number
AU2021213840A1
AU2021213840A1 AU2021213840A AU2021213840A AU2021213840A1 AU 2021213840 A1 AU2021213840 A1 AU 2021213840A1 AU 2021213840 A AU2021213840 A AU 2021213840A AU 2021213840 A AU2021213840 A AU 2021213840A AU 2021213840 A1 AU2021213840 A1 AU 2021213840A1
Authority
AU
Australia
Prior art keywords
seq
acid sequence
amino acid
set forth
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021213840A
Other languages
English (en)
Inventor
Margaret Karow
Jackie SHENG
Richard YAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Zelgen Biopharmaceutical Co Ltd
Original Assignee
Suzhou Zelgen Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Zelgen Biopharmaceutical Co Ltd filed Critical Suzhou Zelgen Biopharmaceutical Co Ltd
Publication of AU2021213840A1 publication Critical patent/AU2021213840A1/en
Assigned to SUZHOU ZELGEN BIOPHARMACEUTICALS CO. LTD. reassignment SUZHOU ZELGEN BIOPHARMACEUTICALS CO. LTD. Request for Assignment Assignors: GENSUN BIOPHARMA INC.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electric Double-Layer Capacitors Or The Like (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2021213840A 2020-01-31 2021-02-01 Bispecific T cell engagers Pending AU2021213840A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062968999P 2020-01-31 2020-01-31
US62/968,999 2020-01-31
PCT/US2021/016104 WO2021155380A1 (en) 2020-01-31 2021-02-01 Bispecific t cell engagers

Publications (1)

Publication Number Publication Date
AU2021213840A1 true AU2021213840A1 (en) 2022-09-29

Family

ID=77079996

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021213840A Pending AU2021213840A1 (en) 2020-01-31 2021-02-01 Bispecific T cell engagers

Country Status (7)

Country Link
US (1) US11976133B2 (https=)
EP (1) EP4097135A4 (https=)
JP (1) JP7840516B2 (https=)
KR (1) KR20220162690A (https=)
CN (1) CN115643806A (https=)
AU (1) AU2021213840A1 (https=)
WO (1) WO2021155380A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021008870A2 (pt) 2019-08-12 2021-11-30 Abl Bio Inc Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer.
US12060434B2 (en) * 2020-02-25 2024-08-13 Gensun Biopharma Inc. Trispecific T cell engagers
US12486331B2 (en) * 2020-01-31 2025-12-02 Gensun Biopharma Inc. Bispecific T cell engagers
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
AU2023217790A1 (en) * 2022-02-10 2024-08-22 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Bispecific antigen-binding molecule and use thereof
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
KR20240153575A (ko) 2022-02-23 2024-10-23 암젠 인크 Dll3을 표적화하는 암 치료
US20250249094A1 (en) * 2022-04-08 2025-08-07 The Wistar Institute Of Anatomy And Biology Combinations of Bispecific T cell Engagers and Methods of Use Thereof
WO2023204290A1 (ja) * 2022-04-21 2023-10-26 愛知県 多重特異性ナノ粒子
JP2025516805A (ja) * 2022-05-20 2025-05-30 アイ－エムエービー バイオファーマ ユーエス リミテッド 固形腫瘍を治療する方法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202532431A (zh) * 2023-09-21 2025-08-16 大陸商樂普創一生物科技（上海）有限公司 多特異性抗體及其用途
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025206223A1 (ja) * 2024-03-28 2025-10-02 早智子 月田 抗ヒトクローディン１８．２抗体及びその使用
WO2025222087A2 (en) * 2024-04-19 2025-10-23 The Brigham And Women's Hospital, Inc. Klrb1 binding agents and methods of use thereof
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025264220A1 (en) * 2024-06-20 2025-12-26 Gensun Biopharma Inc. Multi-specific molecules and methods of use and making thereof
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
CN120168667B (zh) * 2025-03-18 2026-04-14 中国科学院近代物理研究所 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370467B1 (en) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
CA2894879A1 (en) * 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
US20200157224A1 (en) * 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
MA51747A (fr) * 2018-02-08 2020-12-16 Amgen Inc Formulation d'anticorps pharmaceutique à ph faible
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Also Published As

Publication number Publication date
EP4097135A4 (en) 2024-07-03
CN115643806A (zh) 2023-01-24
JP7840516B2 (ja) 2026-04-06
KR20220162690A (ko) 2022-12-08
EP4097135A1 (en) 2022-12-07
US11976133B2 (en) 2024-05-07
WO2021155380A1 (en) 2021-08-05
JP2023512297A (ja) 2023-03-24
US20210246222A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
US11976133B2 (en) Bispecific T cell engagers
US12060434B2 (en) Trispecific T cell engagers
JP2022512684A (ja) Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物
US20240092922A1 (en) Anti-tnfrsf9 antibodies and uses thereof
CN120607624A (zh) 具有受限cd3结合的多特异性多肽构建体及其使用方法
US20230220082A1 (en) Anti-pd-1/cd40 bispecific antibodies and uses thereof
WO2022098771A1 (en) Multispecific antibodies and uses thereof
JP2021503911A (ja) 抗ｏｘ４０抗体及びその用途
SG11202111192TA (en) Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies
US20250115668A1 (en) Anti-ctla4/ox40 bispecific antibodies and uses thereof
US9447160B2 (en) Compositions, methods and kits for treatment of cancer and autoimmune diseases
US12486331B2 (en) Bispecific T cell engagers
IL297545A (en) Modified immunoglobulins
RU2859563C2 (ru) Биспецифические антитела к pd-1/cd40 и их применение
US20250388676A1 (en) Binding proteins comprising an anti-immune checkpoint antibody or a fragment thereof and single-chain tnfrsf ligand multimers
WO2022156773A1 (en) Protein complexes targeting il12 pathway
US20250388703A1 (en) Multi-specific molecules and mentod of use and making thereof
HK40082389A (en) Modified immunoglobulins
WO2025106598A1 (en) Modified mana-tces targeting tumor antigens and engaging t cell receptors, and methods of using thereof
CN120981572A (zh) 具有改进的稳定性的il-2变体及其组合物
HK40094278B (zh) 包含配体-受体对和生物功能蛋白的融合蛋白

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SUZHOU ZELGEN BIOPHARMACEUTICALS CO. LTD.

Free format text: FORMER APPLICANT(S): GENSUN BIOPHARMA INC.